BACKGROUND: Aerobic exercise typically decreases blood glucose levels in individuals with type 1 diabetes. It is currently unknown if glucose responses to exercise and recovery differ between patients on multiple daily insulin injections (MDI) and continuous subcutaneous insulin infusion (CSII). SUBJECTS AND METHODS: Nineteen (16 male, three female) physically active individuals with type 1 diabetes took part in this observational study. Interstitial glucose levels (blinded) were compared during 45 min of standardized aerobic exercise (cycling or running at 60% peak aerobic capacity) and during 6 h of postexercise recovery between individuals using MDI (n=9) and CSII (n=10) therapy. RESULTS: Both MDI and CSII groups had similar reductions in glucose levels during exercise, but responses in early and late recovery differed (group × time interaction, P<0.01). Participants using MDI had greater increases in glucose throughout recovery compared with individuals with CSII. Two-thirds of the MDI patients experienced late-onset post-exercise hyperglycemia (blood glucose >12 mmol/L) compared with only 1/10(th) of the CSII patients (P<0.01). CONCLUSIONS: Among individuals performing regular moderate-to-heavy intensity aerobic exercise, use of CSII helped to limit post-exercise hyperglycemia compared with MDI therapy and is not associated with increased risk for post-exercise late-onset hypoglycemia.
BACKGROUND: Aerobic exercise typically decreases blood glucose levels in individuals with type 1 diabetes. It is currently unknown if glucose responses to exercise and recovery differ between patients on multiple daily insulin injections (MDI) and continuous subcutaneous insulin infusion (CSII). SUBJECTS AND METHODS: Nineteen (16 male, three female) physically active individuals with type 1 diabetes took part in this observational study. Interstitial glucose levels (blinded) were compared during 45 min of standardized aerobic exercise (cycling or running at 60% peak aerobic capacity) and during 6 h of postexercise recovery between individuals using MDI (n=9) and CSII (n=10) therapy. RESULTS: Both MDI and CSII groups had similar reductions in glucose levels during exercise, but responses in early and late recovery differed (group × time interaction, P<0.01). Participants using MDI had greater increases in glucose throughout recovery compared with individuals with CSII. Two-thirds of the MDIpatients experienced late-onset post-exercise hyperglycemia (blood glucose >12 mmol/L) compared with only 1/10(th) of the CSII patients (P<0.01). CONCLUSIONS: Among individuals performing regular moderate-to-heavy intensity aerobic exercise, use of CSII helped to limit post-exercise hyperglycemia compared with MDI therapy and is not associated with increased risk for post-exercise late-onset hypoglycemia.
Authors: Naglaa Ibrahim Mesbah; Nehad Abd-El-Raheem Taha; Zahra Nema Rahme; Faten Fawzi Sukkar; Dina Mohamed Omar Journal: Med Princ Pract Date: 2019-09-27 Impact factor: 1.927
Authors: Sybil A McAuley; Jodie C Horsburgh; Glenn M Ward; André La Gerche; Judith L Gooley; Alicia J Jenkins; Richard J MacIsaac; David N O'Neal Journal: Diabetologia Date: 2016-05-11 Impact factor: 10.122
Authors: Michael R Rickels; Stephanie N DuBose; Elena Toschi; Roy W Beck; Alandra S Verdejo; Howard Wolpert; Martin J Cummins; Brett Newswanger; Michael C Riddell Journal: Diabetes Care Date: 2018-05-18 Impact factor: 19.112
Authors: Michael Müller-Korbsch; Lisa Frühwald; Michael Heer; Maria Fangmeyer-Binder; David Reinhart-Mikocki; Peter Fasching Journal: J Diabetes Sci Technol Date: 2019-10-04
Authors: Kamuran Turksoy; Elif S Bayrak; Lauretta Quinn; Elizabeth Littlejohn; Derrick Rollins; Ali Cinar Journal: Ind Eng Chem Res Date: 2013-09-04 Impact factor: 3.720